Stock Quote

Regeneron's COVID-19 Treatment Gets Emergency FDA Approval

The U.S. Food and Drug Administration has issued emergency use authorization for Regeneron Pharmaceuticals, Inc.'s COVID-19 antibody cocktail. Regeneron shares closed $518.74 on Friday, a gain of $4.03 prior to Saturday night's announcement.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.